Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890100090> ?p ?o ?g. }
- W2890100090 endingPage "1350" @default.
- W2890100090 startingPage "1338" @default.
- W2890100090 abstract "Platinum-based doublet chemotherapy regimens, preferentially gemcitabine plus cisplatin, are generally considered the first-line standard of care for patients with recurrent or metastatic nasopharyngeal carcinoma. However, no consensus has been reached regarding treatment following progression after first-line therapy. Camrelizumab (SHR-1210) is a humanised anti-programmed death-1 (anti PD-1) antibody. We present safety and preliminary antitumour activity of camrelizumab alone as second-line therapy in patients with recurrent or metastatic nasopharyngeal carcinoma and combined with gemcitabine and cisplatin as first-line therapy in this patient population.We report the results from two single-arm, phase 1 trials. Both trials included patients aged 18-70 years with histologically or cytologically confirmed nasopharyngeal carcinoma and confirmed metastatic disease or locoreginal recurrence, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients who received at least one previous line of treatment were enrolled at five academic hospitals in China into the dose-escalation and expansion trial to receive camrelizumab monotherapy intravenously at escalating doses of 1 mg/kg, 3 mg/kg, and 10 mg/kg, and a bridging dose of 200 mg per dose once every 2 weeks (monotherapy trial). Treatment-naive patients were enrolled from a single centre in China to receive six cycles of camrelizumab 200 mg (day 1), gemcitabine 1 g/m2 (days 1 and 8), and cisplatin 80 mg/m2 (day 1) every 3 weeks followed by camrelizumab 200 mg maintenance once every 3 weeks (combination trial). The primary endpoint of both trials was the safety and tolerability of the study treatment. Analyses were done per protocol. Both trials are registered with ClinicalTrials.gov, number NCT02721589 (camrelizumab monotherapy trial) and NCT03121716 (camrelizumab combination trial). Both trials are ongoing, but are no longer enrolling patients.In the camrelizumab monotherapy trial, between March 31, 2016, and Sept 20, 2017, 121 patients were assessed for eligibility, of whom 93 patients were enrolled across the dose-escalation and expansion cohorts and received at least one dose of camrelizumab (safety population). 15 (16%) of 93 patients had treatment-related adverse events of grade 3 or 4, the most common of which were elevated conjugated bilirubin concentration (three [3%] of 93 patients), stomatitis, anaemia, and increased concentrations of aspartate aminotransferase, alanine aminotransferase, and total bilirubin, each of which occurred in two (2%) patients. Eight (9%) patients had a treatment-related serious adverse event. No dose-limiting toxic effects were observed during the dose-escalation phase. 31 (34%; 95% CI 24-44) of 91 evaluable patients on camrelizumab monotherapy had an overall response with a median follow-up of 9·9 months (IQR 8·1-11·7). In the camrelizumab combination trial, between April 18, 2017, and Aug 15, 2017, 24 patients were assessed for eligibility, of whom 23 patients were enrolled and treated (safety population). 20 (87%) of 23 patients had grade 3 or 4 treatment-related adverse events: neutropenia (13 [57%] of 23 patients), anaemia (11 [48%] patients), leucopenia (11 [48%] patients), thrombocytopenia (seven [30%] patients), oedema (two [9%] patients), hyponatraemia (two [9%] patients), hypochloraemia (one [4%] patients), and rash (one [4%] patient). Two patients had treatment-related serious adverse events. No treatment-related deaths occurred in these trials. 20 (91% [95% CI 72-97]) of 22 evaluable patients had an overall response with a median follow-up time of 10·2 months (IQR 9·7-10·8).Camrelizumab is a well tolerated, potential treatment option for patients with recurrent or metastatic nasopharyngeal carcinoma. The combination of camrelizumab plus gemcitabine and cisplatin has a manageable toxicity profile and promising preliminary antitumour activity for this disease in treatment-naive patients. Randomised controlled trials are needed to further establish the role of immune checkpoint inhibition for nasopharyngeal carcinomas.Hengrui Medicine Co, Chinese National Natural Science Foundation project, Science and Technology Program of Guangdong, Pearl River Nova Program of Guangzhou." @default.
- W2890100090 created "2018-09-27" @default.
- W2890100090 creator A5002816521 @default.
- W2890100090 creator A5003608372 @default.
- W2890100090 creator A5013715130 @default.
- W2890100090 creator A5020252828 @default.
- W2890100090 creator A5023899283 @default.
- W2890100090 creator A5044447392 @default.
- W2890100090 creator A5046131158 @default.
- W2890100090 creator A5049834834 @default.
- W2890100090 creator A5052901056 @default.
- W2890100090 creator A5066716873 @default.
- W2890100090 creator A5067131328 @default.
- W2890100090 creator A5067253443 @default.
- W2890100090 creator A5068044246 @default.
- W2890100090 creator A5070121957 @default.
- W2890100090 creator A5073070877 @default.
- W2890100090 creator A5086758549 @default.
- W2890100090 creator A5091143438 @default.
- W2890100090 date "2018-10-01" @default.
- W2890100090 modified "2023-10-17" @default.
- W2890100090 title "Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials" @default.
- W2890100090 cites W1757407923 @default.
- W2890100090 cites W1968120911 @default.
- W2890100090 cites W1969040638 @default.
- W2890100090 cites W1990153402 @default.
- W2890100090 cites W2031391029 @default.
- W2890100090 cites W2035756742 @default.
- W2890100090 cites W2086147326 @default.
- W2890100090 cites W2104350866 @default.
- W2890100090 cites W2110002578 @default.
- W2890100090 cites W2122652710 @default.
- W2890100090 cites W2140040590 @default.
- W2890100090 cites W2147240268 @default.
- W2890100090 cites W2150434794 @default.
- W2890100090 cites W2166662937 @default.
- W2890100090 cites W2168805345 @default.
- W2890100090 cites W2169440736 @default.
- W2890100090 cites W2259982983 @default.
- W2890100090 cites W2329751444 @default.
- W2890100090 cites W2401455386 @default.
- W2890100090 cites W2418354692 @default.
- W2890100090 cites W2512237822 @default.
- W2890100090 cites W2529484692 @default.
- W2890100090 cites W2589293436 @default.
- W2890100090 cites W2612419201 @default.
- W2890100090 cites W2725398806 @default.
- W2890100090 cites W2747016053 @default.
- W2890100090 cites W2747272999 @default.
- W2890100090 cites W2766430096 @default.
- W2890100090 cites W2766816570 @default.
- W2890100090 cites W2789258259 @default.
- W2890100090 cites W2792937256 @default.
- W2890100090 cites W2794739281 @default.
- W2890100090 cites W2796582438 @default.
- W2890100090 cites W2797675588 @default.
- W2890100090 cites W4210983491 @default.
- W2890100090 cites W4235546527 @default.
- W2890100090 doi "https://doi.org/10.1016/s1470-2045(18)30495-9" @default.
- W2890100090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30213452" @default.
- W2890100090 hasPublicationYear "2018" @default.
- W2890100090 type Work @default.
- W2890100090 sameAs 2890100090 @default.
- W2890100090 citedByCount "318" @default.
- W2890100090 countsByYear W28901000902018 @default.
- W2890100090 countsByYear W28901000902019 @default.
- W2890100090 countsByYear W28901000902020 @default.
- W2890100090 countsByYear W28901000902021 @default.
- W2890100090 countsByYear W28901000902022 @default.
- W2890100090 countsByYear W28901000902023 @default.
- W2890100090 crossrefType "journal-article" @default.
- W2890100090 hasAuthorship W2890100090A5002816521 @default.
- W2890100090 hasAuthorship W2890100090A5003608372 @default.
- W2890100090 hasAuthorship W2890100090A5013715130 @default.
- W2890100090 hasAuthorship W2890100090A5020252828 @default.
- W2890100090 hasAuthorship W2890100090A5023899283 @default.
- W2890100090 hasAuthorship W2890100090A5044447392 @default.
- W2890100090 hasAuthorship W2890100090A5046131158 @default.
- W2890100090 hasAuthorship W2890100090A5049834834 @default.
- W2890100090 hasAuthorship W2890100090A5052901056 @default.
- W2890100090 hasAuthorship W2890100090A5066716873 @default.
- W2890100090 hasAuthorship W2890100090A5067131328 @default.
- W2890100090 hasAuthorship W2890100090A5067253443 @default.
- W2890100090 hasAuthorship W2890100090A5068044246 @default.
- W2890100090 hasAuthorship W2890100090A5070121957 @default.
- W2890100090 hasAuthorship W2890100090A5073070877 @default.
- W2890100090 hasAuthorship W2890100090A5086758549 @default.
- W2890100090 hasAuthorship W2890100090A5091143438 @default.
- W2890100090 hasConcept C126322002 @default.
- W2890100090 hasConcept C141071460 @default.
- W2890100090 hasConcept C143998085 @default.
- W2890100090 hasConcept C197934379 @default.
- W2890100090 hasConcept C203092338 @default.
- W2890100090 hasConcept C2776694085 @default.
- W2890100090 hasConcept C2778239845 @default.
- W2890100090 hasConcept C2778375690 @default.
- W2890100090 hasConcept C2778997737 @default.
- W2890100090 hasConcept C2780258809 @default.